San Francisco, CA Clinical Trials Report — July 2026

San Francisco participants should act now if they match a study closing within the next 90 days: 51 recruiting trials are approaching their enrollment deadlines, including 13 that accept healthy volunteers. The city has 1,176 recruiting studies across 411 research facilities, giving patients and volunteers a broad range of local options.

San Francisco opened 22 new trials in July, up from 20 in May. New openings have fluctuated during 2026, from 37 in February and 30 in March to 20 in June. The July increase suggests that local research activity remains strong even as some studies move toward enrollment deadlines.

Closing-soon studies create the most immediate opportunities

People with cancer, lupus nephritis, prostate conditions, heart rhythm problems, or other listed conditions should contact study teams promptly. Trials can stop enrolling before a projected deadline if they reach their participant target.

• Cancer (4 closing trials)
• Endometrial cancer (2)
• Lupus nephritis (2)
• Prostate cancer (2)
• Aging (1)
• Alcohol drinking (1)
• Adolescent behavior (1)
• Stable angina (1)
• Advanced medullary thyroid cancer (1)
• Atrial fibrillation (1)

Healthy volunteers have a separate reason to move quickly. 13 of the closing-soon studies accept healthy participants, while 147 healthy-volunteer trials are recruiting across San Francisco overall. Screening may include age requirements, medical history, medication restrictions, laboratory tests, and time commitments.

Major July openings include a Phase 3 cancer study

Drug studies led July’s new-trial activity with 8 openings, followed by 7 device studies, 5 classified as other, and 3 behavioral studies. The month’s conditions included PTSD, menopause, anorexia nervosa, astrocytoma, endometriosis, auditory hallucinations, and body-composition changes.

• NCT07720284 is AstraZeneca’s Phase 3 study of dato-DXd plus rilvegostomig versus standard care for adults with high-risk muscle-invasive urothelial cancer after surgery. The study plans to enroll 915 participants and evaluates treatment over a program lasting about 78 months.
• NCT07682896 is a Phase 2 study of YB-101 for Graves’ disease, sponsored by Yarrow Bioscience. It plans to enroll 232 participants and will assess thyroid effects, safety, tolerability, and how the treatment moves through the body.
• NCT07682454 is a UCSF-sponsored Phase 2 feasibility study using imaging and intra-arterial nitroglycerin to assess blood-flow changes in hepatocellular carcinoma. It is planned as a single-center study with 50 participants.
• NCT07687238, sponsored by the University of California, San Francisco, studies how active assistance with social and economic support services may improve health for hospitalized children and their families. The study plans to enroll 1,880 participants.
• NCT07680244 evaluates PathFinder 1.0 on CIRRUS 6000 and CIRRUS 5000 devices to detect retinal abnormalities in optical coherence tomography scans. Carl Zeiss Meditec-Dublin CoCe sponsors the study, which plans to include 400 participants.
• NCT07690579 examines social, structural, and lifestyle drivers of prostate cancer disparities. The UCSF-sponsored study plans to enroll 350 participants.

University of California, San Francisco sponsors 10 of July’s new studies, more than any other listed sponsor. Nutraland USA sponsors 2, while the remaining new studies include industry, academic, and other sponsor categories. Overall, 14 new trials are categorized as other and 8 as industry-sponsored.

UCSF dominates local access to research

UCSF-affiliated sites account for the largest concentration of recruiting studies in San Francisco. The University of California, San Francisco lists 262 trials, while University of California San Francisco lists 154. These listings may represent distinct records or affiliated research operations, so prospective participants should confirm the exact location with each study team.

• University of California, San Francisco (262 trials)
• University of California San Francisco (154)
• UCSF Medical Center-Mission Bay (41)
• Kaiser Permanente-San Francisco (37)
• UCSF (33)
• California Pacific Medical Center-Pacific Campus (26)
• UCSF Helen Diller Family Comprehensive Cancer Center (25)
• Research Site (25)
• University of California (21)
• Zuckerberg San Francisco General Hospital (21)
• UCSF Medical Center (18)
• UCSF Benioff Children’s Hospital (15)

UCSF’s network offers particularly accessible options for oncology, children’s health, imaging, endocrinology, and community-health research. Kaiser Permanente-San Francisco, California Pacific Medical Center, Zuckerberg San Francisco General Hospital, and the UCSF Helen Diller Family Comprehensive Cancer Center provide additional local entry points.

Healthy volunteers, families, and older adults can search now

Four of July’s 22 new trials accept healthy volunteers. Six include children, two are female-only, one is male-only, and 18 include older adults. These categories describe study eligibility broadly; each trial may apply narrower age, sex, health, or scheduling requirements.

Families may find the hospitalized-children study especially relevant, while healthy adults can review the growing pool of volunteer studies before enrollment windows narrow. People with cancer, endometrial cancer, lupus nephritis, prostate cancer, or cardiovascular conditions should prioritize closing-soon listings and ask whether local screening appointments remain available.

California alternatives for people willing to travel

San Francisco is not the only strong research market in California. Nearby cities with recruiting studies include Los Angeles (25), San Diego (16), Palo Alto and Duarte (10 each), La Jolla and Sacramento (8 each), and Anaheim and Stanford (7 each). Palo Alto and Stanford may be practical alternatives for Bay Area residents seeking additional academic-site options.

As August approaches, participants should expect the local pipeline to keep changing: new studies may open while current trials reach enrollment targets. Checking eligibility early and contacting both the study team and the listed facility will give interested San Francisco residents the best chance to secure a screening appointment.